Lung cancer overview

Lung cancer, cancer causes of death in both men and women, as it comes first, followed by the three major cancer-breast, colon, and prostate-emerges as the more deadly type of cancer.
Especially for lung cancer, including non-asbestos, Rodon preparers, such as the role of environmental factors also need to also have a genetic predisposition to bahsedilse, as well as the emergence of the disease, is thought to play an important role in the progression and prognosis. Degradation of the complex functions of cell cycle regulators in lung cancer is associated with exactly.
Histologically and clinically classifiable as non-small cell and small cell lung cancer, neuroendocrine also has a subtype.
The search for genetic analysis, except for the normal respiratory epithelium, precancerous lesions, and metastases in advanced cancers covers. In addition, there are many cell line studies, thanks to these studies in the laboratory, cancer cells can be created, and on the various research.
Some genetic disorders are associated with a particular subtype. such as loss of function of p53 gene in tumor prevention in all types of cancer has been recognized as a general feature. Of these p53 protein and epidermal growth factor receptor (EGFR) gene has a separate importance. Finding the levels of expression of these genes, as well as transmitting information about the course of the disease, but also determines the treatment strategy. Such as gefitinib and erlotinib are used in lung cancer "medicine" for the blockade of EGFR molecules are molecules produced. Treatment with the EGFR mutation analysis can be used to test the sensitivity of these molecules. In our laboratory, tumor tissue samples obtained from the DNA of the EGFR gene (18-21. Exons) that are important series of mutations detected by analyzing the response to treatment.
Another problem encountered in the treatment of cancer patients in the long-term therapy is the development of drug resistance. This genetic mechanism in the development of resistance (20 ekzondaki of secondary T790M mutation) is illuminated. The work, created by the resistance to deal with this second generation of genetically modified molecules (lapatinib, etc.). Created.
Another prominent research KRAS'tır cancer gene. Of antibodies against EGFR, KRAS mutations are associated with resistance. Today, genetic studies performed on this gene (especially 12.13 and 61 codon mutations) are used as predictors of treatment response prediction and monitoring of treatment. In our laboratory, the tumor tissue by analyzing DNA samples from a series of anti-EGFR, KRAS gene mutations that are important in the response to treatment is determined.
In addition, mutations in other cancer genes of importance to determine the original treatment BRAF'tır. Some of the molecules used in the treatment of cancer (MEK inhibitor) increased the expression BRAF'ın aims. BRAF'ın genetic analysis of this before starting treatment (V600) is advisable to look. BRAF V600 mutation in our laboratory, studied with sequence analysis.
As a result,
In 2012 the United States only for non-small cell lung cancer is expected to exceed $ 4 billion spent on pharmaceutical expenditures. The discovery of new therapeutic approaches are urgently needed medical point of view. Diagnostic and therapeutic importance could sense a number of genes being studied. Final success criteria and targets to be achieved in the cure, that is, the disappearance of the disease fully.